Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

ures before complete patient access to Esbriet is achieved.
  • Mid-Sized Countries (MSC) – In addition to the seven MSC for which Esbriet pricing has been secured, the company anticipates launches in the remaining three MSC of Netherlands, Finland and Ireland by mid-2013, assuming that acceptable pricing and reimbursement conditions are negotiated in these countries.
  • Enrollment of InterMune's Phase 3 pirfenidone study, ASCEND, in the United States and certain additional territories was completed in January 2013.  ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration with a primary endpoint of change in forced vital capacity (FVC) between baseline and Week 52.  The trial enrolled IPF patients with mild-to-moderate impairment in lung function and certain characteristics that the company believes enhance the probability of a successful study outcome.  Top-line results are expected in Q2 of 2014.
  • On January 22, 2013, InterMune completed a public offering of 15,525,000 shares of its common stock, including the underwriters' over-allotment, with net proceeds to the company of $145.7 million (after payment of underwriting discounts and commissions, and expenses).  InterMune also completed a concurrent public offering of $120.75 million aggregate principal amount of the company's 2.50% convertible Senior Notes due 2017, including the Note underwriters' over-allotment, with net proceeds to the company of $116.7 million (after payment of the underwriting discounts and commissions, and expenses).  The company has used proceeds from the convertible notes offering to repurchase and cancel $66.6 million of its outstanding $85.0 million aggregate principal amount 2015 Notes, and intends to repurchase the remaining $18.4 million of the outstanding 2015 Notes over time.
  • On February 14, 2013 InterMune announced that Sean P. Nolan has joined the company as Executive Vice President and Chief B
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this ... James L. Sherley, director of the Adult Stem Cell ... an often overlooked and under appreciated unique property of ... by Distributed Stem Cells: Misunderstood in the Past, Important ... to congress participants. He gave the address at ...
    (Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ... The only negative is the housing market remaining soft. ...
    (Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
    (Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
    Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
    ... Jan. 11, 2011 Reportlinker.com announces that ... in its catalogue: Sample ... (Results of The Kalorama Survey of Labs) ... Sample preparation and library preparation are ...
    ... of Chemistry Dunwei Wang has received a career award ... energy technology research and expand the community outreach programs ... on developing novel technologies for clean energy applications, has ... a flexible webbing of nano-scale wires that has shown ...
    ... N.C., Jan. 10, 2011 Takeda Pharmaceutical Company ... they have entered into an exclusive, worldwide licensing ... for the risk of Alzheimer,s disease in high-risk ... study pioglitazone in connection with the TOMM40 biomarker ...
    Cached Biology Technology:Reportlinker Adds Sample Preparation and Library Preparation for DNA Sequencers (Results of The Kalorama Survey of Labs) 2Reportlinker Adds Sample Preparation and Library Preparation for DNA Sequencers (Results of The Kalorama Survey of Labs) 3Developer of 'nanonets' snares National Science Foundation Career Award 2Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone 2
    (Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
    (Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
    (Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
    Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
    ... a majority of hip fracture patients of all ages and ... a new study presented today at the 2013 Annual Meeting ... whether or not living in a warm, sunny climate improves ... vitamin D levels of 1,539 patients, including 448 acute hip ...
    ... environmental engineer has received a three-year, $561,730 grant to identify ... water providers can take action to contain and curb the ... Foundation have awarded Assistant Professor Hyeok Choi the grant to ... exist so that the harmful algae can be monitored. , ...
    ... Some diseases are caused by single gene mutations. Current ... produce hundreds of potential gene candidates, making it difficult ... a team of researchers led by Rockefeller University scientists ... the hunt for disease-causing genes. The investigation, spearheaded ...
    Cached Biology News:UT Arlington engineer to search for bad algal blooms 2Researchers create map of 'shortcuts' between all human genes 2Researchers create map of 'shortcuts' between all human genes 3
    E1A (adenovirus early region 1)...
    ... 1 ( Abpromise for all tested ... peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK EDILYHFNLT TSRHNFPALF GDVKFVCVGG ... acids 1-99 of Human Uridine Phosphorylase 1 ... 7378 Swiss Protein ID: ...
    Nucleobindin 1 [NUCB1]...
    Presenilin-1, N-terminus....
    Biology Products: